Mechanism of host defense suppression induced by viral infection: mode of action of inosiplex as an antiviral agent. 1982

H Ohnishi, and H Kosuzume, and H Inaba, and M Okura, and Y Morita, and H Mochizuki, and Y Suzuki

The mechanism of influenza virus (INFV)-induced immunosuppression and the mode of inosiplex action against INFV infection were studied. INFV suppressed both anti-lipopolysaccharide and anti-sheep erythrocyte antibody production in mice. INFV infection caused viral mRNA synthesis and increased total RNA synthesis in lymphocytes, but total mRNA synthesis was decreased. The translational ability of INFV-infected lymphocytes was also suppressed. Thus, INFV seemed to cause suppression of both mRNA synthesis and the translational ability of lymphocytes, resulting in suppression of lymphocyte functions. Inosiplex potentiated antibody production against sheep erythrocytes but not against lipopolysaccharide in normal and INFV-infected mice. Adamantanamine did not produce such a potentiating effect. The lymphocytes obtained from INFV-immunized and inosiplex-treated mice conferred resistance against INFV infection. This resistance was partially inhibited by anti-Thy 1.2 antibody treatment of the lymphocytes. In an adoptive cell transfer system, inosiplex treatment of T-cell donors potentiated antibody production when a non-immunosuppressive carrier (human serum albumin) was used. When an immunosuppressive carrier (INFV) was used, inosiplex treatment of either B-cell donors or T-cell donors increased antibody production. Direct introduction of inosiplex into lymphocytes by a cell fusion technique stimulated anti-sheep erythrocyte antibody production more effectively than the addition of inosiplex to cultures. Inosiplex increased total RNA and total mRNA syntheses in phytohemagglutinin-treated lymphocytes. In INFV-infected lymphocytes, inosiplex decreased syntheses of total RNA, total mRNA, and viral mRNA and restored translational ability. From these results, we concluded that inosiplex penetrates into lymphocytes and suppresses viral RNA synthesis and that it supports lymphocyte functions by promoting RNA synthesis and translational ability, both of which are necessary for hosts.

UI MeSH Term Description Entries
D007108 Immune Tolerance The specific failure of a normally responsive individual to make an immune response to a known antigen. It results from previous contact with the antigen by an immunologically immature individual (fetus or neonate) or by an adult exposed to extreme high-dose or low-dose antigen, or by exposure to radiation, antimetabolites, antilymphocytic serum, etc. Immunosuppression (Physiology),Immunosuppressions (Physiology),Tolerance, Immune
D007116 Immunization, Passive Transfer of immunity from immunized to non-immune host by administration of serum antibodies, or transplantation of lymphocytes (ADOPTIVE TRANSFER). Convalescent Plasma Therapy,Immunoglobulin Therapy,Immunotherapy, Passive,Normal Serum Globulin Therapy,Passive Antibody Transfer,Passive Transfer of Immunity,Serotherapy,Passive Immunotherapy,Therapy, Immunoglobulin,Antibody Transfer, Passive,Passive Immunization,Therapy, Convalescent Plasma,Transfer, Passive Antibody
D007288 Inosine A purine nucleoside that has hypoxanthine linked by the N9 nitrogen to the C1 carbon of ribose. It is an intermediate in the degradation of purines and purine nucleosides to uric acid and in pathways of purine salvage. It also occurs in the anticodon of certain transfer RNA molecules. (Dorland, 28th ed)
D007542 Inosine Pranobex An alkylamino-alcohol complex of inosine used in the treatment of a variety of viral infections. Unlike other antiviral agents, it acts by modifying or stimulating cell-mediated immune processes rather than acting on the virus directly. Inosiplex,Methisoprinol,Imunovir,Isoprinosin,Isoprinosine,Methysoprinol,Metisoprinol,NPT-10381,NPT 10381,NPT10381,Pranobex, Inosine
D008214 Lymphocytes White blood cells formed in the body's lymphoid tissue. The nucleus is round or ovoid with coarse, irregularly clumped chromatin while the cytoplasm is typically pale blue with azurophilic (if any) granules. Most lymphocytes can be classified as either T or B (with subpopulations of each), or NATURAL KILLER CELLS. Lymphoid Cells,Cell, Lymphoid,Cells, Lymphoid,Lymphocyte,Lymphoid Cell
D008811 Mice, Inbred DBA An inbred strain of mouse. Specific substrains are used in a variety of areas of BIOMEDICAL RESEARCH such as DBA/1J, which is used as a model for RHEUMATOID ARTHRITIS. Mice, DBA,Mouse, DBA,Mouse, Inbred DBA,DBA Mice,DBA Mice, Inbred,DBA Mouse,DBA Mouse, Inbred,Inbred DBA Mice,Inbred DBA Mouse
D009976 Orthomyxoviridae Infections Virus diseases caused by the ORTHOMYXOVIRIDAE. Orthomyxovirus Infections,Infections, Orthomyxoviridae,Infections, Orthomyxovirus,Swine Influenza,Infection, Orthomyxoviridae,Infection, Orthomyxovirus,Influenza, Swine,Orthomyxoviridae Infection,Orthomyxovirus Infection
D005260 Female Females
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000917 Antibody Formation The production of ANTIBODIES by proliferating and differentiated B-LYMPHOCYTES under stimulation by ANTIGENS. Antibody Production,Antibody Response,Antibody Responses,Formation, Antibody,Production, Antibody,Response, Antibody,Responses, Antibody

Related Publications

H Ohnishi, and H Kosuzume, and H Inaba, and M Okura, and Y Morita, and H Mochizuki, and Y Suzuki
September 1963, Science (New York, N.Y.),
H Ohnishi, and H Kosuzume, and H Inaba, and M Okura, and Y Morita, and H Mochizuki, and Y Suzuki
December 1974, Science (New York, N.Y.),
H Ohnishi, and H Kosuzume, and H Inaba, and M Okura, and Y Morita, and H Mochizuki, and Y Suzuki
March 1979, The American journal of clinical nutrition,
H Ohnishi, and H Kosuzume, and H Inaba, and M Okura, and Y Morita, and H Mochizuki, and Y Suzuki
November 1979, The American journal of clinical nutrition,
H Ohnishi, and H Kosuzume, and H Inaba, and M Okura, and Y Morita, and H Mochizuki, and Y Suzuki
December 2003, Nihon Geka Gakkai zasshi,
H Ohnishi, and H Kosuzume, and H Inaba, and M Okura, and Y Morita, and H Mochizuki, and Y Suzuki
May 2006, Medical science monitor : international medical journal of experimental and clinical research,
H Ohnishi, and H Kosuzume, and H Inaba, and M Okura, and Y Morita, and H Mochizuki, and Y Suzuki
January 1993, Advances in experimental medicine and biology,
H Ohnishi, and H Kosuzume, and H Inaba, and M Okura, and Y Morita, and H Mochizuki, and Y Suzuki
January 1986, Voprosy meditsinskoi khimii,
H Ohnishi, and H Kosuzume, and H Inaba, and M Okura, and Y Morita, and H Mochizuki, and Y Suzuki
November 2017, Trends in cell biology,
H Ohnishi, and H Kosuzume, and H Inaba, and M Okura, and Y Morita, and H Mochizuki, and Y Suzuki
March 2003, Antiviral research,
Copied contents to your clipboard!